Covaxin: Bharat Biotech gets nod from DCGI panel for Phase III trials

The nod is subject to amendment in how primary efficacy endpoint for symptomatic cases be studied in Phase 3 trials, the panel further stated.

from Hindustan Times - india https://ift.tt/2HoFUiA